Showing results (921-930 of 1,211) with videos related to
Sort By:
Pageof 122
European Heart Journal|June 8, 2022
Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trialMarco Metra, Matteo Pagnesi, Brian L Claggett, et al.JACC. Heart Failure|August 12, 2019
Design of a "Lean" Case Report Form for Heart Failure Therapeutic DevelopmentMitchell A Psotka, Mona Fiuzat, Peter E Carson, et al.The New England Journal of Medicine|November 3, 2009
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney diseaseMarc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 23, 2018
Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Finnian R Mc Causland, Brian Claggett, Emmanuel A Burdmann, et al.JAMA Cardiology|May 22, 2023
Contemporary Use of Sodium-Glucose Cotransporter-2 Inhibitor Therapy Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in the US: The Get With The Guidelines-Heart Failure RegistryJacob B Pierce, Muthiah Vaduganathan, Gregg C Fonarow, et al.Journal of Cardiac Failure|August 17, 2025
Growth differentiation factor-15 and the effect of dapagliflozin in heart failure: insights from the DAPA-HF trialDavid D Berg, Kieran Docherty, Atefeh Talebi, et al.JACC. Heart Failure|April 4, 2024
Dapagliflozin and Timing of Prior Heart Failure Hospitalization: A Patient-Level Meta-Analysis of DAPA-HF and DELIVERJawad H Butt, Pardeep S Jhund, Kieran F Docherty, et al.JAMA Cardiology|January 24, 2024
Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction: A Post Hoc Analysis of the DELIVER TrialOrly Vardeny, Akshay S Desai, Pardeep S Jhund, et al.Circulation. Heart Failure|August 30, 2024
Relationship Between Cardiac Structure and Function With Renal Function Trajectory and Outcomes in Patients With Heart Failure: Insights From the PARAGON-HF TrialHenri Lu, Safia Chatur, Sahmin Lee, et al.Journal of Cardiac Failure|April 18, 2025
NT-proBNP in the Early Convalescent Phase after High-Risk Myocardial Infarction Is Associated with Adverse Cardiovascular Outcomes: the PARADISE-MI TrialKarola S Jering, Brian L Claggett, Eugene Braunwald, et al.Pageof 122